1 / 1

NT CVD : Development and Validation of new Diagnostic, Preventive and Therapeutic Tools for the Prevention of Cardiovasc

2. 1. 4. 3. 6. 7. 5. NT CVD : Development and Validation of new Diagnostic, Preventive and Therapeutic Tools for the Prevention of Cardiovascular Disease in Chronic Kidney Disease. COORDINATION: J. Jankowski (Charité) | CO-COORDINATION: T. Krahn (Bayer-Schering-Pharma)

thu
Télécharger la présentation

NT CVD : Development and Validation of new Diagnostic, Preventive and Therapeutic Tools for the Prevention of Cardiovasc

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2 1 4 3 6 7 5 NTCVD: Development and Validation of new Diagnostic, Preventive and Therapeutic Tools for the Prevention of Cardiovascular Disease in Chronic Kidney Disease COORDINATION: J. Jankowski (Charité) | CO-COORDINATION: T. Krahn (Bayer-Schering-Pharma) PARTNER: V. Jankowski, K. Lehmann (Charite) | H. Bruck (Universitätsklinikum Essen) | R. Herweg (MPI MolGen) | H. Lemke (EXcorLab) PRINCIPAL INVESTIGATORS • Prof. Dr. Jankowski, Dr. Jankowski, Charité, Medizinische Klinik IV, Berlin • Dr. Lehmann, PD Dr. Buschmann, Charité, Center for Cardiovascular Research, Berlin • PD Dr. Herget-Rosenthal, Universitätsklinikum Essen, Klinik für Nephrologie • Prof. Dr. Lehrach, Dr. Herwig, Max-Planck-Institut Berlin, Molecular Genetics • Dr. Lemke, EXcorLab GmbH, Obernburg • Dr. Krahn, Bayer Schering Pharma, Wuppertal • 7. Associated Partner: Membrana GmbH, Wuppertal Figure 2: General approaches of NTCVD CONCLUSION This project aims to use proven and in some instances proprietary molecular, genomic and proteomic approaches to identify and characterize the unknown mediators potentially involved in the accelerated CVD in CKD (stage 3-5). Furthermore the consortium will have to characterize known mediators in detail with respect to their cardiovascular effects. The findings and results will culminate in the conception and development of innovative tools to diagnose, prevent and treat CVD in CKD patients. Figure 1: Organization Chart of the Consortium ■SME ■Clinic ■University■Research Institute ■Industry■Molecular Phenotyping■Application Development – Work Package Partner –Work Package Leader → Informational Flow SUMMARY The consortium will apply the novel tools “proteomics, peptidomics, metabonomics and genotyping”, which allow assessing the complete transcription and translation of the genomic capital to elucidate the genetic and physiological background of CVD in CKD patients. This approach is focused on human samples i.e. tissues, cells and body fluids as humoral targets are altered in CVD of CKD patients. NTCVD applies "forward genetics" from phenotype to gene to remedy the causes of the enormously accelerated cardiovascular morbidity and death in CKD (stage 3-5) and to develop novel diagnostics and therapeutics, based on molecular genotyping and phenotyping. This will be done (A) by elucidating the role of recently identified mediators relating to CVD in CKD by using bioassay approaches and pattern analysis of CKD patient samples, and (B) by the identification of yet unknown mediators. Correspondence: Prof. Dr. Joachim Jankowski, Charité, Med Klinik IV, Hindenburgdamm 30, 12200 Berlin, Germany; Joachim.Jankowski@charite.de

More Related